Basic Adoport Information

• INN (International Nonproprietary Name): Tacrolimus
• Brand Names Available In United Kingdom: Prograf®, Advagraf®, Tacni®, Modigraf®, and generic tacrolimus (Sandoz, Mylan, Accord)
• ATC Code: L04AD02
• Forms & Dosages: Immediate-release capsules 0.5mg, 1mg, 5mg; extended-release tablets/capsules 0.5mg, 1mg, 3mg, 5mg; granules for oral suspension 0.2mg and 1mg sachets; injection vials 5mg/mL.
• Manufacturers In United Kingdom: Astellas Pharma (Prograf®, Advagraf®) and multiple generic suppliers (Sandoz, Mylan, Accord, Teva) are listed as global suppliers; local UK-specific manufacturer listing not specified.
• Registration Status In United Kingdom: Not specified in the provided dataset; EMA/EMA approvals and national licences referenced in raw data.
• OTC / Rx Classification: Prescription-only medicine (Rx only / POM).

Critical Warnings & Restrictions

Tacrolimus is a potent immunosuppressant used to prevent organ rejection and carries serious risks that require specialist oversight.

Major risks include increased susceptibility to infections, nephrotoxicity, neurotoxicity and an increased long‑term risk of malignancy.

Patients must be started, titrated and monitored by transplant teams or specialist clinicians in the NHS and must not alter dosing or obtain tacrolimus from non‑NHS sources without clinician approval.

Therapeutic drug monitoring is mandatory; regular trough blood levels are required to adjust dosing with target ranges varying by organ and time post‑transplant.

Urgent action is needed for unexplained fever, sore throat, cough, reduced urine output, new severe tremor, visual disturbance or seizure — seek same‑day advice from the transplant clinic or contact NHS 111/out‑of‑hours services.

Vaccinations: avoid live vaccines unless the transplant team expressly advises; follow the vaccination plan agreed with specialists.

Pregnancy and breastfeeding require consultant review; tacrolimus carries infection and developmental risks and specialist obstetric/transplant co‑management is essential.

Concomitant nephrotoxic drugs increase kidney risk — ensure a pharmacist or doctor reviews all medicines including OTC and herbal products.

Use a checklist at initiation: baseline renal and liver function, plan for trough levels, infection prophylaxis, contraception advice and vaccination record.

A monitoring schedule table and checklist should be used and documented in the patient record for clear follow‑up.

High‑Risk Groups

Elderly patients are more susceptible to nephrotoxicity, infections and clinically significant drug interactions and often require lower starting doses and closer monitoring.

Pregnancy: tacrolimus is used in pregnant transplant recipients but requires specialist obstetric and transplant co‑management with more frequent level checks because pregnancy alters pharmacokinetics.

Breastfeeding: specialist advice is required as some tacrolimus is excreted in breastmilk and a careful risk–benefit decision is needed.

Chronic liver disease: hepatic impairment reduces metabolism (CYP3A4) and increases toxicity risk; reduce starting dose and increase monitoring frequency.

Renal impairment: tacrolimus may worsen renal function; dose changes are guided by trough concentrations rather than blanket formulaic reductions.

Paediatric patients often need higher mg/kg doses and very frequent level checks.

Use the simple checklist below before each clinic decision:

• Age and frailty status
• Pregnancy and breastfeeding status
• Liver and renal function results
• History of infections or malignancy
• All current medicines including OTC and herbal
• Vaccination record

Multidisciplinary review and documentation in the NHS electronic record are recommended for all high‑risk patients.

Interaction With Activities

Tacrolimus frequently causes tremor, dizziness, visual disturbance or drowsiness at initiation or with toxicity and these effects can impair driving or machine operation.

Under UK law patients must not drive if their condition or medication affects their ability to drive safely; notify the DVLA only if a clinician advises or if seizures/blackouts occur.

Employers should be informed when workplace safety could be affected, for example in roles with manual handling or operating machinery.

A phased return to work and referral to occupational health are useful for safety‑critical roles.

Keep a symptom diary and use a workplace safety checklist to document symptoms and performance issues.

Pharmacists and clinicians should record counselling about driving and provide written advice for employers if requested.

• Impairment: a reduction in ability to perform tasks safely (e.g., due to tremor or dizziness).
• Side Effect: an expected drug reaction that may or may not affect function (e.g., mild tremor).

Contact points: transplant clinic or transplant nurse for urgent advice, NHS DVLA guidance pages for driving questions, and occupational health for workplace assessment.

Q&A — “Can I Drive After Taking It In The UK?”

Short answer: drive only if you feel safe and are free of side effects that impair driving such as tremor, dizziness, blurred vision or drowsiness.

If tacrolimus causes significant neurological symptoms stop driving and contact your transplant team or GP for assessment.

You usually do not need to notify the DVLA solely for tacrolimus unless you develop seizures, blackouts or other conditions requiring statutory notification — follow your clinician’s advice.

Keep a written record of counselling from your clinician or pharmacist for work or insurance purposes.

Checklist before you drive: presence of symptoms, recent dose changes, recent trough level results and clinician confirmation that driving is safe.

Usage Basics

What is adoport and how is it presented?

INN: tacrolimus, often seen under Prograf®, Advagraf®/Astagraf XL® (prolonged‑release) and multiple generics such as Tacrolimus Sandoz® or Tacrolimus Mylan®.

Formulations available include immediate‑release capsules, extended‑release tablets/capsules, oral granules and intravenous vials.

Legal classification: tacrolimus is a Prescription‑Only Medicine (POM) in the UK and should be prescribed by a specialist or GP using NHS e‑prescription or paper prescription.

Do not switch formulations without specialist approval — immediate‑release and prolonged‑release products are not interchangeable without clinician oversight.

• Immediate‑Release: capsules taken twice daily.
• Extended‑Release: once‑daily prolonged‑release formulations for some patients.
• Granules: single‑dose sachets for mixing when capsules cannot be swallowed.
• Injection: IV vials for inpatient use.

Available strengths and packaging notes include capsules 0.5mg, 1mg and 5mg; granules 0.2mg and 1mg sachets; and injections commonly 5mg/mL in vials.

ATC code is L04AD02, placing tacrolimus among calcineurin inhibitors in immunosuppressants.

Brand Names Available In The United Kingdom

Common brands seen in UK practice are Prograf® (immediate‑release and injectable) and Advagraf® (extended‑release), together with several generics from manufacturers such as Sandoz, Mylan and Accord.

Granules like Modigraf® and Prograf® granules are used for patients who cannot swallow capsules, including paediatric cases.

Hospital initiations usually use the brand supplied by the hospital pharmacy and community pharmacies dispense the brand prescribed by the clinician.

Always check labels carefully: extended‑release and immediate‑release formulations have different dosing intervals and must not be swapped without advice.

Dosing Guide

Dosing is individualised by weight, indication and trough concentrations and must be adjusted by the transplant team.

Typical starting oral doses from standard guidance include kidney transplant 0.1–0.2 mg/kg/day divided twice daily, liver transplant 0.10–0.15 mg/kg/day divided twice daily and heart/lung typically 0.075–0.15 mg/kg twice daily.

Target trough levels depend on organ and time since transplant: early higher targets (for example 5–20 ng/mL) then lower maintenance ranges (for example 3–15 ng/mL depending on centre protocol).

Children often require higher mg/kg doses and more frequent monitoring.

Checklist for dose change triggers: abnormal trough level, rising creatinine, signs of neurotoxicity, or starting/stopping an interacting drug.

Never change brand or formulation without specialist approval; formulation switches require re‑titration and close blood‑level monitoring.

Q&A — “What If I Miss A Dose?”

If you miss a dose and remember within a few hours take it as soon as you remember.

If it is close to the next scheduled dose skip the missed dose and continue the usual schedule; do not double the next dose.

For granules or liquid forms follow transplant clinic guidance on administration timing.

If several doses have been missed or you vomit shortly after dosing contact the transplant team or local pharmacy promptly; do not attempt to self‑correct.

Document missed doses for clinic review; frequent missed dosing requires urgent clinic contact, possible level checks and assessment of graft risk.

Interaction Chart

Tacrolimus is a substrate for CYP3A4 and P‑glycoprotein and is subject to clinically important drug interactions.

Strong CYP3A4 inhibitors increase tacrolimus levels and can cause toxicity; dose reduction and close monitoring are required if these drugs are started.

Strong inducers reduce tacrolimus exposure and risk graft rejection if levels fall; avoid or adjust with specialist supervision.

Grapefruit and grapefruit juice significantly increase tacrolimus exposure and should be avoided.

• Common hazardous combinations include azole antifungals plus tacrolimus and certain macrolide antibiotics; report changes to clinic immediately.
• Report suspected interactions or adverse events to the MHRA Yellow Card scheme.

Food And Drinks

Avoid grapefruit and Seville oranges as they increase tacrolimus exposure.

Take tacrolimus consistently with regard to meals according to clinic instructions because high‑fat meals can alter absorption.

Caffeine does not have a major pharmacokinetic interaction but may worsen tremor.

Alcohol: limit to moderate intake, avoid binge drinking and report any liver‑related symptoms to your transplant team.

For granules mixed with food follow the product leaflet and transplant nurse instructions precisely.

User Reports & Trends

Patients commonly report tremor and insomnia on initiation, frustration with frequent blood draws and anxiety about infections.

Forum themes and patient sites mention confusion when brands change and questions about online purchases and cost.

Clinicians note improved adherence with prolonged‑release formulations such as Advagraf® and Envarsus XR® for some patients.

• Positives: effective prevention of rejection, improved quality of life when stable.
• Negatives: side‑effects (tremor, GI upset), interaction burden and monitoring fatigue.

Use patient‑reported outcome checklists in clinic to capture sleep, tremor, GI symptoms, mood and adherence.

Encourage reporting of adverse events to the MHRA Yellow Card and participation in transplant support groups run by NHS trusts.

Access & Purchase Options

In the UK tacrolimus is initially supplied by hospital pharmacies after transplant and many patients move to community pharmacy dispensing once stable.

Major high‑street chains such as Boots and LloydsPharmacy and independent community pharmacies provide dispensing, repeat services and adherence support.

Patients should be warned about rogue online sellers and unlicensed imports; verify suppliers carefully.

In our online pharmacy, adoport is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Checklist for safe ordering: verify MHRA‑approved supplier, valid prescription, pharmacist counselling and clear labelling of formulation and strength.

For cost concerns discuss generics and prescription exemptions with your GP or local medicines optimisation team.

Boots, LloydsPharmacy, Superdrug And Community Pharmacies

High‑street chains provide repeat prescription services, dispensing in original packaging, adherence packaging and sometimes home delivery.

Hospital to community transfer is commonly governed by a shared care arrangement with a written plan and monitoring schedule.

• Services offered: medication review, dose reminders, home delivery.
• Documents to bring: hospital letter, current clinic contact details and a list of current medicines.

Online Pharmacies And NHS E‑Prescriptions

EPS (Electronic Prescription Service) allows secure transfer of prescriptions to a nominated pharmacy for collection or delivery.

Accredited UK online pharmacies may dispense with EPS or a valid paper prescription; always check GPhC registration and request pharmacist counselling.

Hospital pharmacies can provide an urgent bridging supply if community or online services are delayed.

Mechanism & Pharmacology

Tacrolimus is a calcineurin inhibitor that blocks calcineurin in T lymphocytes, reducing IL‑2 transcription and T‑cell activation — a key mechanism for preventing allograft rejection.

Oral absorption is variable and affected by food; tacrolimus is metabolised in the liver mainly by CYP3A4 and eliminated primarily in bile.

A narrow therapeutic index and variable pharmacokinetics necessitate trough (pre‑dose) monitoring.

IV formulations exist for inpatient use and prolonged‑release products aim to reduce trough variability and improve adherence.

• Calcineurin Inhibitor: reduces T‑cell activation so graft rejection is less likely.
• Trough Level: pre‑dose blood concentration used to guide dose.
• Mechanism explains monitoring needs and common adverse effects such as nephrotoxicity, neurotoxicity, hyperglycaemia and hypertension.

Indications & Off‑Label Uses

Licensed indications in the UK and internationally include prevention of organ rejection in kidney, liver and heart transplants and other solid organ transplants as per product licences.

Tacrolimus is usually part of combination regimens with steroids and antimetabolites such as mycophenolate or azathioprine for long‑term graft protection.

Off‑label systemic uses occur in specialist contexts and include some refractory autoimmune conditions, but systemic off‑label prescribing requires documented local governance and informed consent.

• Pros of off‑label use: potential benefit in refractory disease under specialist supervision.
• Cons: limited licence evidence for indication, increased monitoring and regulatory documentation needed.

Clarification: “Licensed” means an approved indication and product licence; “off‑label” refers to use outside that licence and needs explicit governance and consent.

Key Clinical Findings

Recent UK and EU data from 2022–2025 reinforce the central role of therapeutic drug monitoring (TDM) to balance rejection risk with toxicity.

Studies show prolonged‑release formulations can improve adherence and stabilise troughs for some patients compared with immediate‑release capsules such as Prograf®.

Registries report that most interaction‑related admissions involve antifungal and antiviral agents affecting tacrolimus levels.

• Key themes: TDM importance, formulation choices affecting adherence, and interaction‑related adverse events.
• Recommendation: follow local transplant protocols and NHS/ESC/ERA guidance for centre‑specific target ranges and monitoring plans.

Alternatives Matrix

NHS alternatives include ciclosporin, mTOR inhibitors such as sirolimus or everolimus, mycophenolate mofetil or sodium, and biologics for select indications.

Switching from tacrolimus requires multidisciplinary review, hospital monitoring and re‑titration with frequent trough measurements.

Decision checklist: prior rejection history, renal function, comorbidities, drug interactions and patient preference.

NHS Prescribing Alternatives

Always consult local formulary and pharmacy before switching therapies.

Common Questions

FAQ 1: Will tacrolimus make me more likely to get infections?

Yes; tacrolimus suppresses the immune system and increases susceptibility to infections; report fevers and respiratory symptoms promptly and follow prophylaxis/vaccination plans.

FAQ 2: Can I take other medicines like antibiotics or antifungals?

Some antibiotics and antifungals interact strongly with tacrolimus; always check with your pharmacist or transplant clinic before starting any new medicine.

FAQ 3: Are prolonged‑release forms better?

Prolonged‑release forms can improve adherence and may reduce peak‑to‑trough variability for some patients but must be prescribed specifically and not swapped without clinician approval.

FAQ 4: Do I need long‑term blood tests?

Yes; regular trough level monitoring and renal and liver blood tests are mandatory for safety and dose optimisation.

Micro‑FAQ: Can I take vaccines?

Avoid live vaccines unless advised by your transplant team; inactivated vaccines are usually recommended per specialist guidance.

Patient actions checklist before clinic: bring an up‑to‑date drug list, recent symptoms, adherence notes and any blood test results.

NHS Cost & Access Comparison Table

To reduce cost check prescription exemption status, consider generics and discuss options with your GP or medicines optimisation team.

Registration & Regulation

MHRA oversees regulation and tacrolimus products carry national or central authorisations; prescribing should follow product information and local transplant centre protocols.

Off‑label use requires documented local governance and informed consent and pharmacists must verify GPhC registration for online suppliers.

Report serious adverse reactions to the MHRA Yellow Card scheme; both patients and clinicians are encouraged to report.

• Regulatory steps: licensing, prescribing oversight, pharmacovigilance.
• Prescriber checklist: informed consent, monitoring plan, patient information and documentation.

Storage & Handling

Store capsules and granules at 20–25°C and protect from moisture and light; do not refrigerate.

Injection vials should be stored according to manufacturer instructions and not frozen.

In the UK’s damp climate keep medicines in the original packaging in a cool, dry place away from bathrooms.

Transport at ambient temperature; for travel carry medicines in original labelled containers and a clinic letter for customs or emergency care.

Unused medicines should be returned to a pharmacy for safe disposal; do not flush them down the toilet.

Guidelines For Proper Use

Pharmacist counselling checklist at dispensing: confirm indication, brand/formulation, dosing schedule, administration timing relative to meals and missed dose advice.

Highlight major interactions such as grapefruit, azoles, rifampicin and St John’s wort and warn about side‑effect signs requiring urgent review.

Provide written leaflets and encourage patients to carry a medication card with drug name, formulation and transplant clinic contact details for A&E visits.

For adherence suggest pill boxes, smartphone reminders and community pharmacy repeat dispensing or EPS nominations.

• Shared Care: a written plan between hospital and community clinicians for monitoring and prescribing.
• EPS: electronic prescription service for secure transfer to nominated pharmacy.
• TDM: therapeutic drug monitoring of trough levels.

Encourage reporting side effects to the MHRA Yellow Card and use NHS pharmacy medicine reviews regularly.

Delivery Across United Kingdom